Filing Details

Accession Number:
0001209191-22-038451
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-06-21 16:57:02
Reporting Period:
2022-06-17
Accepted Time:
2022-06-21 16:57:02
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1557746 Aclaris Therapeutics Inc. ACRS () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1172252 N Andrew Schiff C/O Aclaris Therapeutics, Inc.
640 Lee Road, Suite 200
Wayne PA 19087
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2022-06-17 19,565 $15.14 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 634,455 Indirect By Aisling Capital IV LP
Footnotes
  1. These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2022.
  2. The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $15.00 to $15.35, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. The reportable securities are owned directly by Aisling Capital IV, LP ("Aisling"), and held indirectly by Aisling Capital Partners IV, LP ("Aisling GP"), as general partner of Aisling, Aisling Capital Partners IV LLC ("Aisling Partners"), as general partner of Aisling GP, and each of the individual managing members of Aisling Partners. The individual managing members (collectively, the "Managers") of Aisling Partners are Dr. Andrew Schiff and Steve Elms. Aisling GP, Aisling Partners, and the Managers share voting and dispositive power over the shares directly held by Aisling. Dr. Schiff disclaims beneficial ownership of these securities and this report is not an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.